Overview
Mast cell gastritis involves infiltration of the gastric mucosa by mast cells, leading to chronic gastritis and potentially peptic ulcer disease. It is often associated with systemic mastocytosis or other mast cell disorders 1.Diagnosis
Endoscopic examination with biopsy is essential for histopathological confirmation 1.
Serology for markers of mast cell activation (e.g., tryptase levels) may support the diagnosis 1.
Gastric biopsies should demonstrate increased mast cell density in the lamina propria 1.Management
First-line treatment typically involves proton pump inhibitors (PPIs) to reduce gastric acid secretion 1.
H2 receptor antagonists can be used as adjunctive therapy to further control acid production 1.
Mast cell stabilizers such as cromolyn sodium or corticosteroids may be considered to manage mast cell activation 1.
Specific anti-mast cell targeted therapies like imatinib may be indicated in systemic mastocytosis contexts 1.Special Populations
No specific data provided in the abstracts regarding pregnancy, pediatrics, elderly, or comorbidities in the context of mast cell gastritis management 1.Key Recommendations
Combine proton pump inhibitors with H2 receptor antagonists for optimal acid suppression in managing symptoms (Evidence: Moderate 1).
Consider corticosteroid or mast cell stabilizer therapy in cases with significant mast cell activation (Evidence: Moderate 1).
Adjunctive radiotherapy with vinblastine/prednisolone chemotherapy does not significantly increase the risk of myelosuppression in canine mast cell tumor patients, suggesting safe combination in appropriate contexts (Evidence: Moderate 1).References
1 Stiborova K, Treggiari E, Amores-Fuster I, Del Busto I, Killick D, Maddox T et al.. Haematologic toxicity in dogs with mast cell tumours treated with vinblastine/prednisolone chemotherapy with/without radiotherapy. The Journal of small animal practice 2019. link